Clinical trialPhase 1Terminated
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.
- Outcome
- Stopped earlyThe decision was not based on any safety concerns (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 6 October 2023
- Expected end
- 13 December 2024
- Enrollment
- 24 participants
- Sites
- 5
- Primary outcomes
- Incidence and severity of dose limiting toxicities of 177Lu-FF58; Incidence and severity of adverse events and serious adverse events of 177Lu-FF58; Dose modifications for 177Lu-FF58; Dose intensity for 177Lu-FF58
- Sponsor
- Industry
- Results posted
- No
- Last update
- 24 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of the study is to test the safety and dosing of \[177Lu\]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent \[68Ga\]Ga-FF58 including its ability to identify tumor lesions and its safety profile.
Detailed description public domain (ClinicalTrials.gov)
The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will be screened with a \[68Ga\]Ga-FF58 positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan to assess eligibility for treatment with \[177Lu\]Lu-FF58. In the escalation part, different doses of \[177Lu\]Lu-FF58 will be tested to identify the recommended dose. The expansion part of the study will examine the safety and preliminary efficacy of \[177Lu\]Lu-FF58 at the recommended dose determined during the escalation part. The end of study will occur when at least 80% of the patients in the expansion part have completed the follow-up for disease progression or discontinued from the study for any reason, and all patients have completed treatment and the 36 month long term follow- up period, or the study is terminated early in which case all patients would also be followed up for safety.